Lars Nieba named Engimmune chief executive

19 April 2023

Engimmune Therapeutics, a biotech developing novel T-cell receptor (TCR)-based therapies, has announced the appointment of Lars Nieba (pictured above) as chief executive.

Søren Mouritsen, co-founder and previous chief executive of the privately-held Swiss firm, is stepping down in a planned transition.

"His leadership, financial and biopharmaceutical expertise will be invaluable as Engimmune progresses to the next stages of development"Dr Nieba’s 25 years of experience in biopharma leadership has come in R&D, business and clinical development, venture capital, manufacturing and product strategy. He has been chief executive at Norwegian biopharma Nordic Nanovector (FRA: 8NN) and held previous positions in big pharma and VC firms including Roche (ROG: SIX), Bayer (BAYN: DE) and Pureos Bioventures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK